BMJ Open

Effects of respiratory rehabilitation for patients with novel coronavirus (COVID-19) pneumonia in the rehabilitation phase: Protocol for a systematic review and meta-analysis

Journal:	*BMJ Open*
Manuscript ID	bmjopen-2020-039771
Article Type:	Protocol
Date Submitted by the Author:	28-Apr-2020
Complete List of Authors:	Zhu, Feilong; Xuzhou Medical University, The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University Zhang, Ming; Xuzhou Medical University, The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University Chen, Wei; Xuzhou Medical University, The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University Zeng, Cheng; THE FIRST HOSPITAL OF PUTIAN CITY Wang, Dan; Xuzhou Medical University, The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University Hong, Qianqin; Xuzhou Medical University, The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University
Keywords:	Rehabilitation medicine < INTERNAL MEDICINE, Respiratory infections < THORACIC MEDICINE, Public health < INFECTIOUS DISEASES

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Effects of respiratory rehabilitation for patients with novel coronavirus (COVID-19) pneumonia in the rehabilitation phase: Protocol for a systematic review and meta-analysis

Feilong Zhu,[1] Ming Zhang,[1,2] Wei Chen,[1,2,※] Cheng Zeng,[3] Dan Wang,[1] Qianqin Hong[1]

[1]The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University, Xuzhou Rehabilitation Hospital, Xuzhou, China

[2]Department of Rehabilitation Medicine, XUZHOU CENTRAL HOSPITAL, 199 Jiefang South Road, Xuzhou, Jiangsu 221009, P.R. China

[3]THE FIRST HOSPITAL OF PUTIAN CITY, Putian, China

※Correspondence to

Wei Chen; E-mail: chenwei2339@163.com

Prepublication history and additional materials for this paper are available online. To view these materials, please visit the BMJ Open journal online.

Word count

2000 words

ABSTRACT

Introduction: Recent viral pneumonia infected by Coronavirus Disease 2019 (COVID-19) has attracted the attention of people all over the world. We aim to investigate the effects of respiratory rehabilitation therapy on patients with novel coronavirus by conducting this systematic review and meta-analysis.

Methods and analysis: Ethics approval is not required because this is a protocol for a systematic review and meta-analysis. This systematic review and meta-analysis has been registered in the PROSPERO. The PubMed, Embase, Web of Science, the Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Wanfang and VIP information databases will be searched from their inception time to April 15, 2020 without restricting research types to find relevant studies. Two reviewers will independently extract data and perform quality assessment of included studies. Review Manager 5.3 software (Cochrane Collaboration) and Stata 16.0 software will be used to conduct this meta-analysis. Mean difference (MD) or standardized mean difference (SMD) with 95% confidence intervals (CI) is used for calculating continuous variables to synthesize data.

Ethics and dissemination: Ethical approval is not required because this meta-analysis is based on published papers. The results of this systematic review and meta-analysis will be published in a peer-reviewed journal once we have finished this study.

PROSPERO registration number: CRD42020180214.

Keywords: novel coronavirus pneumonia, lung function, respiratory rehabilitation, physical therapy

Strengths and limitations of this study

This will be the first systematic review and meta-analysis to investigate the effects of respiratory rehabilitation therapy on patients with novel coronavirus pneumonia.

To avoid errors, data extraction and bias assessment will be carried out by two reviewers independently.

Egger's test and Begg's test will be conducted to assess the publication bias with Stata 16.0 software.

Absent of sufficient randomized controlled trials may be a limitation for this meta-analysis.

INTRODUCTION

In the late of December 2019, patients with viral pneumonia infected by subsequently named Coronavirus Disease 2019 (COVID-19) were reported in Wuhan, China.[1] COVID-19 virus has sparked a pandemic around the world and millions of people have been infected.[2] It is still remain difficult to manage and control COVID-19 for countries around the world.[3] Patients who suffered from 2019 novel coronavirus had clinical manifestations of cough, shortness of

breath, chest pain and so forth.[4] COVID-19 is a highly contagious respiratory infection disease that can cause physical, respiratory and psychological disorders.[5] It is of great importance to provide the pulmonary rehabilitation methods for patients with viral pneumonia caused by COVID-19.[6] Respiratory rehabilitation is crucial to the recovery of patients during clinical treatment and in the rehabilitation phase.[7] Early rehabilitation services can improve distressing physical and psychological symptoms with lung diseases.[8] Previously, pulmonary rehabilitation and chest physical therapy have been proved that can provide greatest positive effects for chronic obstructive pulmonary disease (COPD) or other chronic respiratory diseases.[9 10] However, it is unclear whether respiratory rehabilitation therapy could improve the lung function in patients with coronavirus pneumonia. Additionally, up to now, there is no systematic review and meta-analysis which investigates the association between respiratory rehabilitation therapy and COVID-19. Therefore, we will qualitatively and quantitatively investigate the effects of respiratory rehabilitation therapy on patients with novel coronavirus in this systematic review and meta-analysis.

METHODS

Registration

This systematic review and meta-analysis protocol has been registered in the PROSPERO and the registration number is CRD42020180214. The protocol

will follow the guideline of the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA-P).[11]

Patient and Public Involvement

No patient involved.

Search strategy

The PubMed, Embase, Web of Science, the Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Wanfang and VIP information databases will be searched from their respective inception dates to April 15, 2020. Studies about the effects of respiratory rehabilitation programs for patients with Coronavirus Disease 2019 in the rehabilitation phase will be included in this meta-analysis, including randomized controlled trials (RCTs), controlled clinical trials (CCTs), prospective and retrospective comparative cohort studies, cluster trials, cross sectional studies and observational studies. The detailed information of PubMed search strategy is shown (table 1).

Table 1 Search strategy of PubMed

Search	Query
#1	"COVID-19"[Mesh Terms]
#2	"2019 nCoV"[Title/Abstract] OR "2019nCoV"[Title/Abstract] OR "2019 novel coronavirus"[Title/Abstract] OR "COVID 19"[Title/Abstract] OR "COVID19"[Title/Abstract] OR "new coronavirus"[Title/Abstract] OR "novel coronavirus"[Title/Abstract] OR "SARS CoV-2"[Title/Abstract] OR "(Wuhan[Title/Abstract] AND coronavirus)[Title/Abstract]" OR "COVID-19"[Title/Abstract]

	OR “SARS-CoV”[Title/Abstract] OR “2019-nCoV”[Title/Abstract] OR “SARS-CoV-2”[Title/Abstract] OR “novel coronavirus pneumonia” [Title/Abstract] OR “COVID-19 pneumonia” [Title/Abstract]
#3	“Respiratory rehabilitation”[Title/Abstract] OR “pulmonary rehabilitation”[Title/Abstract] OR “Respiratory therapy”[Title/Abstract] OR “pulmonary recovery”[Title/Abstract] OR “pulmonary rehabilitation program”[Title/Abstract] OR “physiotherapy”[Title/Abstract] OR “physical therapy”[Title/Abstract] OR “physical intervention”[Title/Abstract] OR “physical rehabilitation”[Title/Abstract] OR “pulmonary Therapy”[Title/Abstract] OR “pulmonary intervention”[Title/Abstract] OR “respiratory intervention”[Title/Abstract]
#4	#1 OR #2
#5	#3 AND #4

Eligibility criteria

Study design

Relevant studies including randomized controlled trials (RCTs), controlled clinical trials (CCTs), prospective and retrospective comparative cohort studies, cluster trials, cross sectional studies and observational studies will be included in this meta-analysis. We attempt to search as many types of studies as possible because of absent original research about recently erupted COVID-19.

Participants

The patients who suffered from viral pneumonia affected by Coronavirus Disease 2019 and coordinated with respiratory rehabilitation treatments irrespective of gender and ethnicity will be involved in this meta-analysis.

Interventions

The interventions of respiratory rehabilitation therapy for viral pneumonia could be breathing exercises, respiratory muscle training, chest physiotherapy or other physical training programs.

Outcomes

The outcomes will be considered in this meta-analysis are as follows: forced expiratory volume in one second (FEV_1), forced vital capacity (FVC), the ratio of forced expiratory volume in one second and forced vital capacity (FEV_1/FVC), Rated Perceived Exertion (RPE) scale scores, Borg scale scores, the ratio of ventilation and perfusion (V/Q), blood oxygen saturation and discharge time.

Study selection and data extraction

Study selection

Two reviewers select studies independently and any different opinions between two reviewers should consult with a third reviewer to reach a consensus. We will remove repetitive articles at first and then exclude irrelevant studies through reading the title, abstract and the full text one by one. The study selection process is demonstrated in a PRISMA flow diagram (figure 1).

Data extraction

A standardized form will be used to extract data by two reviewers independently and disagreements between them should be solved with the help of the third reviewer. The detailed extraction information are as follows: the first author, year of publication, country of publication, study design, sample characteristics, number of participants, experimental and control interventions, intervention time, outcomes and results.

Quality assessment of included studies

The Cochrane risk of bias tool with items of random sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting and other bias will be used to assess the quality of included randomized controlled trials. Otherwise, the Newcastle-Ottawa Scale (NOS) which includes consideration of patient selection, study comparability and outcome assessment will be performed to evaluate non-randomized studies quality. We need to select the suitable scale according to the type of included studies.

Data synthesis and statistical analysis

Data synthesis

Review Manager 5.3 software (Cochrane Collaboration) and Stata 16.0 software will be used to conduct this meta-analysis. Mean difference (MD) or standardized mean difference (SMD) with 95% confidence intervals (CI) is used for calculating continuous variables.

Assessment of heterogeneity

Statistical heterogeneity among included studies will be assessed by the chi-square test and I^2 test. We use a fixed-effect model for data analysis at first. If $I^2 > 0.5$ or $P < 0.1$, it is considered that there is a significant heterogeneity among studies and a random effects model will be used without finding suitable reasons for the high heterogeneity.

Subgroup analysis

If the heterogeneity of the included studies is large, subgroup analyses will be carried out by types of respiratory rehabilitation programs.

Sensitivity analysis

Sensitivity analysis is conducted through excluding studies one by one so that we can seek out the source of heterogeneity.

Assessment of publication bias

Egger's test and Begg's test will be conducted to assess the publication bias with Stata 16.0 software.

Ethics and dissemination

Ethical approval is not required because this meta-analysis is based on

published papers. The results of this systematic review and meta-analysis will be published in a peer-reviewed journal once we have finished this study

DISCUSSION

As far as we know, this is the first systematic review and meta-analysis to investigate the effects of respiratory rehabilitation therapy on patients with novel coronavirus pneumonia. Respiratory rehabilitation therapy has been widely applied to chronic respiratory diseases.[12] But, it is uncertain whether respiratory rehabilitation therapy could improve the lung function in patients with coronavirus pneumonia as a result of few original research. This is a problem that we and people from all over the world are worrying about. However, absent of sufficient randomized controlled trials may be a limitation for this meta-analysis.

Author affiliations

[1]The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University, Xuzhou Rehabilitation Hospital, Xuzhou, China

[2]Department of Rehabilitation Medicine, XUZHOU CENTRAL HOSPITAL, 199 Jiefang South Road, Xuzhou, Jiangsu 221009, P.R. China

[3]THE FIRST HOSPITAL OF PUTIAN CITY, Putian, China

Contributions

CW, ZM conceived and designed the study. ZF made the search strategy of databases. WD, HQ, and ZC will be involved in data extraction and the assessment of methodological quality. The protocol manuscripts were finished by ZF. All authors have checked manuscripts and approved the publication of the protocol.

Funding

This work was supported by both [Jiangsu Provincial Medical Youth Talent] grant number [QNRC2016376] and [Xuzhou Medical Young Talents Projects] grant number [2016015].

Competing interests statement

None

REFERENCES

1. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* 2020;395(10224):565-74.
2. Gao Y, Yan L, Huang Y, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. *Science* 2020.
3. Gilbert M, Pullano G, Pinotti F, et al. Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study.

Lancet 2020;395(10227):871-77.

4. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020;395(10223):507-13.

5. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020;579(7798):270-73.

6. Yang F, Liu N, Hu JY, et al. [Pulmonary rehabilitation guidelines in the principle of 4S for patients infected with 2019 novel coronavirus (2019-nCoV)]. *Zhonghua Jie He He Hu Xi Za Zhi* 2020;43(3):180-82.

7. Working Group of Novel Coronavirus PUMCH. [Diagnosis and clinical management of 2019 novel coronavirus infection: an operational recommendation of Peking Union Medical College Hospital (V2.0)]. *Zhonghua Nei Ke Za Zhi* 2020;59(3):186-88.

8. Maddocks M, Lovell N, Booth S, et al. Palliative care and management of troublesome symptoms for people with chronic obstructive pulmonary disease. *Lancet* 2017;390(10098):988-1002.

9. Guan WJ, Zheng XY, Chung KF, et al. Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action. *Lancet* 2016;388(10054):1939-51.

10. Spruit MA, Pitta F, McAuley E, et al. Pulmonary Rehabilitation and Physical Activity in Patients with Chronic Obstructive Pulmonary

Disease. *Am J Respir Crit Care Med* 2015;192(8):924-33.

11. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.

12. Lacasse Y, Wong E, Guyatt GH, et al. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. *Lancet* 1996;348(9035):1115-9.

Figure 1 Flow chart and descriptions of study selection. N, Number.



Figure 1 Flow chart and descriptions of study selection. N, Number.

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item
ADMINISTRATIVE INFORMATION		
Title:		
Identification	1a	Identify the report as a protocol of a systematic review **(YES)**
Update	1b	If the protocol is for an update of a previous systematic review, identify as such
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number **(YES, PROSPERO, CRD42020180214)**
Authors:		
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author **(YES)**
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review **(YES)**
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments **(YES)**
Support:		
Sources	5a	Indicate sources of financial or other support for the review **(YES)**
Sponsor	5b	Provide name for the review funder and/or sponsor **(YES)**
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol **(YES)**
INTRODUCTION		
Rationale	6	Describe the rationale for the review in the context of what is already known **(YES)**
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) **(YES)**
METHODS		
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review **(YES)**
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage **(YES)**
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated **(YES)**
Study records:		

Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review **(YES)**
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) **(YES)**
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators **(YES)**
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications **(YES)**
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale **(YES)**
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis **(YES)**
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised **(YES)**
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2, Kendall's τ) **(YES)**
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) **(YES)**
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned **(YES)**
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) **(YES)**
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE) **(YES)**

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

BMJ Open

Effects of respiratory rehabilitation on patients with novel coronavirus (COVID-19) pneumonia in the rehabilitation phase: protocol for a systematic review and meta-analysis

Journal:	*BMJ Open*
Manuscript ID	bmjopen-2020-039771.R1
Article Type:	Protocol
Date Submitted by the Author:	01-Jun-2020
Complete List of Authors:	Zhu, Feilong; Xuzhou Medical University, The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University Zhang, Ming; Xuzhou Medical University, The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University Gao, Min; Department of Rehabilitation Medicine, XUZHOU CENTRAL HOSPITAL Zeng, Cheng; Department of Rehabilitation Medicine, The First Hospital of Putian City Wang, Dan; Xuzhou Medical University, The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University Hong, Qianqin; Xuzhou Medical University, The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University Chen, Wei; Xuzhou Medical University, The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University
Primary Subject Heading:	Rehabilitation medicine
Secondary Subject Heading:	Global health, Respiratory medicine
Keywords:	Rehabilitation medicine < INTERNAL MEDICINE, Public health < INFECTIOUS DISEASES, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Respiratory infections < THORACIC MEDICINE

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Effects of respiratory rehabilitation on patients with novel coronavirus (COVID-19) pneumonia in the rehabilitation phase: protocol for a systematic review and meta-analysis

Feilong Zhu,[1] Ming Zhang,[1,2] Min Gao,[2,1] Cheng Zeng,[3] Dan Wang,[1] Qianqin Hong,[1] Wei Chen[1,2]

[1]The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University, Xuzhou Rehabilitation Hospital, Xuzhou, China

[2]Department of Rehabilitation Medicine, XUZHOU CENTRAL HOSPITAL, Xuzhou, China

[3]Department of Rehabilitation Medicine, The First Hospital of Putian City, Putian, China

Correspondence to

Wei Chen; chenwei2339@163.com

Prepublication history and additional materials for this paper are available online. To view these materials, please visit the BMJ Open journal online.

Word count

2646 words

ABSTRACT

Introduction: The recent viral pneumonia caused by the coronavirus disease 2019 (COVID-19) has gained the attention of the people all over the world. We aim to investigate the effects of respiratory rehabilitation therapy on patients infected with the novel coronavirus by conducting a systematic review and meta-analysis.

Methods and analysis: This systematic review and meta-analysis have been registered in the International Prospective Register of Systematic Reviews (PROSPERO). The PubMed, Embase, Web of Science, the Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Wanfang Data, and VIP information databases will be searched from inception time to date without restricting research types to find relevant studies. We will also look into reference lists of relevant trials and reviews, and manually search gray literature, such as trial registries. Two reviewers will independently extract data and perform quality assessment of included studies. Review Manager 5.3 (Cochrane Collaboration) and Stata 16.0 software will be utilized to conduct this meta-analysis. The mean difference (MD) or standardized mean difference (SMD) with 95% confidence intervals (CI) is used in the computation of continuous variables to synthesize data.

Ethics and dissemination: Ethical approval is not required due to the nature of this meta-analysis, which is based on published papers. The results of this systematic review and meta-analysis will be published in a peer-reviewed journal once we finish this study.

PROSPERO registration number: CRD42020180214.

Keywords: COVID-19, lung function, respiratory rehabilitation, physical therapy

Strengths and limitations of this study

This will be the first systematic review and meta-analysis investigating the effects of respiratory rehabilitation therapy on patients with novel coronavirus pneumonia.

To avoid errors, data extraction and bias assessment will be independently performed by two reviewers.

Egger's and Begg's tests will be conducted for the assessment of the publication bias under the use of Stata 16.0 software.

The absence of sufficient randomized controlled trials may be a limitation for this meta-analysis.

INTRODUCTION

Toward the end of December 2019, patients with viral pneumonia subsequently infected by the coronavirus disease 2019 (COVID-19) were reported in Wuhan, China.[1] COVID-19 has sparked a pandemic around the world, and millions of people have been infected.[2] The management and control of COVID-19 infection remains a challenge for countries around the world.[3] Patients who suffered from the 2019 novel coronavirus had clinical manifestations of cough, shortness of breath, chest pain, and so on.[4] COVID-19 is a highly contagious respiratory infection disease that can cause physical, respiratory, and psychological disorders.[5] Pulmonary rehabilitation methods are important for patients with viral pneumonia due to by COVID-19.[6] Respiratory

rehabilitation is crucial to the recovery of patients during clinical treatment and rehabilitation phase.[7] Early rehabilitation services can improve distressing physical and psychological symptoms with lung diseases.[8] Previously, pulmonary rehabilitation and chest physical therapy have been proven to provide the most positive effects for chronic obstructive pulmonary disease or other chronic respiratory diseases.[9 10] It was safe and feasible to perform early pulmonary rehabilitation in patients with acute exacerbation of lung diseases, which could effectively improve physical performance and quality of life.[11 12] Respiratory rehabilitation played a vital role in the non-invasive support management.[13-17] However, it is unclear whether respiratory rehabilitation therapy could improve lung function in patients with coronavirus pneumonia. Additionally, up to now, there is no systematic review and meta-analysis investigating the association between respiratory rehabilitation therapy and COVID-19. Therefore, we will qualitatively and quantitatively examine the effects of respiratory rehabilitation therapy on patients with novel coronavirus in this systematic review and meta-analysis.

METHODS

Registration

This systematic review and meta-analysis protocol have been registered in the International Prospective Register of Systematic Reviews (PROSPERO), and the registration number was CRD42020180214. The protocol followed the guideline of the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA-P).[18]

Patient and Public Involvement

No patient involved.

Search strategy

The PubMed, Embase, Web of Science, the Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Wanfang, and VIP information databases will be searched from inception time to date. We will also search for reference lists of relevant trials and reviews, and manually search gray literature, such as trial registries. Studies concerning the effects of respiratory rehabilitation programs for COVID-19 patients in the rehabilitation phase will be included in this meta-analysis, as well as randomized controlled trials (RCTs), controlled clinical trials (CCTs), prospective and retrospective comparative cohort studies, cluster trials, cross-sectional studies, and observational studies. The detailed information of PubMed search strategy is presented in table 1.

Table 1 Search strategy of PubMed

Search	Query
#1	"COVID-19"[Mesh Terms]
#2	"2019 nCoV"[Title/Abstract] OR "2019nCoV"[Title/Abstract] OR "2019 novel coronavirus"[Title/Abstract] OR "COVID19"[Title/Abstract] OR "COVID 19"[Title/Abstract] OR "new coronavirus"[Title/Abstract] OR "novel coronavirus"[Title/Abstract] OR "SARS CoV-2"[Title/Abstract] OR "(Wuhan[Title/Abstract] AND coronavirus)[Title/Abstract]" OR "COVID-19"[Title/Abstract] OR "SARS-CoV"[Title/Abstract] OR "2019-nCoV"[Title/Abstract] OR "SARS-CoV-2"[Title/Abstract] OR "novel coronavirus pneumonia" [Title/Abstract] OR "COVID-19 pneumonia" [Title/Abstract] OR "corona-virus*"[Title/Abstract] OR "coronavirus*"[Title/Abstract] OR "NcovWuhan*"[Title/Abstract] OR "NcovHubei*"[Title/Abstract] OR "NcovChina*"[Title/Abstract] OR "NcovChinese*"[Title/Abstract]

#3	"Respiratory rehabilitation"[Title/Abstract] OR "pulmonary rehabilitation"[Title/Abstract] OR "Respiratory therapy"[Title/Abstract] OR "pulmonary recovery"[Title/Abstract] OR "pulmonary rehabilitation program"[Title/Abstract] OR "physiotherapy"[Title/Abstract] OR "physical therapy"[Title/Abstract] OR "physical intervention"[Title/Abstract] OR "physical rehabilitation"[Title/Abstract] OR "pulmonary Therapy"[Title/Abstract] OR "pulmonary intervention"[Title/Abstract] OR "respiratory intervention"[Title/Abstract] OR "breath*"[Title/Abstract] OR "exercis*"[Title/Abstract] OR "train*"[Title/Abstract] OR "fitness*" [Title/Abstract] OR "aerobic"[Title/Abstract] OR "resistanc*" [Title/Abstract] OR "endurance"[Title/Abstract] OR "inspiratory muscle train*"[Title/Abstract] OR "inspiratory muscle strength" [Title/Abstract] OR "respiratory muscle train*"[Title/Abstract] OR "respiratory muscle strength"[Title/Abstract] OR "respiratory muscle endurance" [Title/Abstract] OR "muscle relaxation therapy" [Title/Abstract] OR "hydrotherapy" [Title/Abstract] OR "swim*" [Title/Abstract] OR "bik*"[Title/Abstract] OR "joy*"[Title/Abstract] OR "walk*"[Title/Abstract] OR "run*"[Title/Abstract] OR "danc*" [Title/Abstract] OR "sport*"[Title/Abstract] OR "active circular breathing technique"[Title/Abstract] OR "ACBT" [Title/Abstract] OR "chest expansion"[Title/Abstract] OR "forced exhalation technique"[Title/Abstract] OR "airway clearance"[Title/Abstract] OR "mechanical cough assist" [Title/Abstract] OR "manual technique"[Title/Abstract] OR "mechanical device"[Title/Abstract] OR "positive expiratory pressure"[Title/Abstract] OR "power breath"[Title/Abstract]
#4	#1 OR #2
#5	#3 AND #4

Eligibility criteria

Study design

Relevant studies, including randomized controlled trials (RCTs), controlled clinical trials (CCTs), prospective and retrospective comparative cohort studies, cluster trials, cross-sectional studies, and observational studies will be included in this meta-analysis. We attempt to search as many types of studies as possible due to the absence of original

research on the recently emerging COVID-19.

Participants

Patients who suffered from viral pneumonia caused by the coronavirus disease 2019 and coordinated with respiratory rehabilitation treatments regardless of section, whether in the intensive care unit (ICU), intermediate respiratory unit, general ward, or rehabilitation facility will be involved in this meta-analysis. There will be no restrictions with respect to gender, age, or ethnicity.

Interventions

The interventions of respiratory rehabilitation therapy for viral pneumonia could be breathing exercises, respiratory muscle training, chest physiotherapy, active circular breathing technique, chest expansion exercises, forced exhalation technique, airway clearance techniques, positive expiratory pressure, using mechanical devices (e.g. mechanical cough assist), exercise training (aerobic exercise or, resistance and endurance training), or other physical training programs.

Outcomes

The primary outcomes of interest will be 6-minute walking distance (6MWD), cardiopulmonary exercise test (CPET), quality of life. The secondary outcomes are as follows: body mass index, arterial partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio, forced expiratory volume in one second (FEV1), forced vital

capacity (FVC), ratio of forced expiratory volume in one second and forced vital capacity (FEV1/FVC), baseline dyspnea index (BDI), rating of perceived exertion scale scores, Borg scale scores, blood oxygen saturation, and discharge time.

Study selection and data extraction

Study selection

Two reviewers independently select studies, and any disagreement between the two reviewers should be consulted by a third reviewer to reach a consensus. We will remove repetitive articles at first and exclude irrelevant studies based on the title, abstract, and the full text. The study selection process is demonstrated in a PRISMA flow diagram (figure 1).

Data extraction

A standardized form will be used by two reviewers to extract data independently, and disagreements between them should be solved with the help of a third reviewer. The detailed extraction information are as follows: the first author, year of publication, country of publication, study design, sample characteristics, number of participants, experimental and control interventions, intervention time, outcomes, and results. We will try our best to contact the corresponding authors of the studies through email to deal with missing data.

Quality assessment of included studies

The Cochrane risk of bias tool with items of random sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, and other biases will be used to assess the quality of included randomized controlled trials. Otherwise, the Newcastle-Ottawa Scale, which includes consideration of patient selection, study comparability, and outcome assessment will be used to evaluate the quality of non-randomized studies. We need to select a suitable scale according to the types of studies included.

Data synthesis and statistical analysis

Data synthesis

Review Manager 5.3 (Cochrane Collaboration) and Stata 16.0 software will be used to conduct this meta-analysis. The mean difference (MD) or standardized mean difference (SMD) with 95% confidence intervals (CI) is used to calculate continuous variables.

Assessment of heterogeneity

Statistical heterogeneity among included studies will be assessed using the chi-squared test and I^2 test. We use a fixed-effect model for data analysis at first. If $I^2 > 0.5$ or $P < 0.1$, it is considered that there is a significant heterogeneity among the studies, and random-effect model will be used without examining the probable cause for the high heterogeneity.[19]

Subgroup analysis

If there is a large heterogeneity in the included studies, subgroup analyses will be performed on different types of respiratory rehabilitation programs and in different treatment locations, such as, intensive care unit (ICU), intermediate respiratory unit, general ward, or rehabilitation facility.

Sensitivity analysis

Sensitivity analysis is conducted by excluding studies one by one, so that we can determine the source of heterogeneity.

Assessment of publication bias

Publication bias will be examined according to the funnel plot method. Also, Egger's test and Begg's test will be conducted to quantitatively assess the publication bias using the Stata 16.0 software.

Quality of evidence

We will use the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) guidelines for the assessment of the strength of evidence for each outcome. The result will be categorized as high, moderate, low, and very low certainty of evidence.[20]

Ethics and dissemination

Ethical approval is not required due to the nature of this meta-analysis, which is based

on published papers. The results of this systematic review and meta-analysis will be published in a peer-reviewed journal once we finish this study.

DISCUSSION

To the best of our knowledge, this is the first systematic review and meta-analysis to investigate the effects of respiratory rehabilitation therapy on patients with novel coronavirus pneumonia. Respiratory rehabilitation therapy has been widely applied to patients with chronic respiratory diseases.[21] However, it is uncertain whether respiratory rehabilitation therapy could improve lung function in patients with coronavirus pneumonia due to limited original research. This is a major concern for us and for everyone around the world. Nonetheless, the lack of sufficient randomized controlled trials may be a limitation for this meta-analysis.

Author affiliations

[1]The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University, Xuzhou Rehabilitation Hospital, Xuzhou, China

[2]Department of Rehabilitation Medicine, XUZHOU CENTRAL HOSPITAL, Xuzhou, China

[3]Department of Rehabilitation Medicine, The First Hospital of Putian City, Putian, China

Acknowledgements

The authors acknowledge Emerald Publishing TSS Dept for help in revising this protocol. We also particularly thank the reviewers and editors for their valuable comments, which helped considerably to improve the quality of the manuscript.

Contributions

CW, ZM conceived and designed the study. ZF made the search strategy of databases. WD, HQ, GM, and ZC will be involved in data extraction and the assessment of methodological quality. The protocol manuscripts were finished by ZF. All authors have checked manuscripts and approved the publication of the protocol.

Funding

This work was supported by both [Jiangsu Provincial Medical Youth Talent] grant number [QNRC2016376] and [Xuzhou Medical Young Talents Projects] grant number [2016015].

Competing interests statement

None declared.

REFERENCES

1. Lu R, Zhao X, Li J, *et al*. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* 2020;395(10224):565-74.
2. Gao Y, Yan L, Huang Y, *et al*. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. *Science* 2020.
3. Gilbert M, Pullano G, Pinotti F, *et al*. Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study. *Lancet* 2020;395(10227):871-77.
4. Chen N, Zhou M, Dong X, *et al*. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020;395(10223):507-13.
5. Zhou P, Yang XL, Wang XG, *et al*. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020;579(7798):270-73.
6. Yang F, Liu N, Hu JY, *et al*. [Pulmonary rehabilitation guidelines in the principle of 4S for patients infected with 2019 novel coronavirus (2019-nCoV)]. *Zhonghua Jie He He Hu Xi Za Zhi* 2020;43(3):180-82.
7. Working Group of Novel Coronavirus PUMCH. [Diagnosis and clinical management of 2019 novel coronavirus infection: an operational recommendation of Peking Union Medical College Hospital (V2.0)]. *Zhonghua Nei Ke Za Zhi* 2020;59(3):186-88.

8. Maddocks M, Lovell N, Booth S, *et al*. Palliative care and management of troublesome symptoms for people with chronic obstructive pulmonary disease. *Lancet* 2017;390(10098):988-1002.

9. Guan WJ, Zheng XY, Chung KF, *et al*. Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action. *Lancet* 2016;388(10054):1939-51.

10. Spruit MA, Pitta F, McAuley E, *et al*. Pulmonary Rehabilitation and Physical Activity in Patients with Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2015;192(8):924-33.

11. He M, Yu S, Wang L, *et al*. Efficiency and safety of pulmonary rehabilitation in acute exacerbation of chronic obstructive pulmonary disease. *Med Sci Monit* 2015;21:806-12.

12. Hoffman M, Chaves G, Ribeiro-Samora GA, *et al*. Effects of pulmonary rehabilitation in lung transplant candidates: a systematic review. *BMJ Open* 2017;7(2):e013445.

13. Lazzeri M, Lanza A, Bellini R, *et al*. Respiratory physiotherapy in patients with COVID-19 infection in acute setting: a Position Paper of the Italian Association of Respiratory Physiotherapists (ARIR). *Monaldi Arch Chest Dis* 2020;90(1).

14. Cilione C, Lorenzi C, Dell Orso D, *et al*. Predictors of change in exercise capacity after comprehensive COPD inpatient rehabilitation. *Med Sci Monit* 2002;8(11):CR740-5.

15. Paneroni M, Simonelli C, Saleri M, *et al*. Short-Term Effects of Normocapnic

Hyperpnea and Exercise Training in Patients With Chronic Obstructive Pulmonary Disease: A Pilot Study. *Am J Phys Med Rehabil* 2018;97(12):866-72.

16. Paneroni M, Simonelli C, Vitacca M, *et al*. Aerobic Exercise Training in Very Severe Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. *Am J Phys Med Rehabil* 2017;96(8):541-48.

17. Vitacca M, Kaymaz D, Lanini B, *et al*. Non-invasive ventilation during cycle exercise training in patients with chronic respiratory failure on long-term ventilatory support: A randomized controlled trial. *Respirology* 2018;23(2):182-89.

18. Moher D, Shamseer L, Clarke M, *et al*. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.

19. Moher D, Liberati A, Tetzlaff J, *et al*. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6(7):e1000097.

20. Guyatt G, Oxman AD, Akl EA, *et al*. GRADE guidelines: Introduction—GRADE evidence profiles and summary of findings tables. *Journal of clinical epidemiology* 2011;64(4):383-94.

21. Lacasse Y, Wong E, Guyatt GH, *et al*. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. *Lancet* 1996;348(9035):1115-9.

Table 1 Search strategy of PubMed

Figure 1 Flow chart and descriptions of study selection. N, Number.



Figure 1 Flow chart and descriptions of study selection. N, Number.

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item
ADMINISTRATIVE INFORMATION		
Title:		
Identification	1a	Identify the report as a protocol of a systematic review **(YES)**
Update	1b	If the protocol is for an update of a previous systematic review, identify as such
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number **(YES, PROSPERO, CRD42020180214)**
Authors:		
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author **(YES)**
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review **(YES)**
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments **(YES)**
Support:		
Sources	5a	Indicate sources of financial or other support for the review **(YES)**
Sponsor	5b	Provide name for the review funder and/or sponsor **(YES)**
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol **(YES)**
INTRODUCTION		
Rationale	6	Describe the rationale for the review in the context of what is already known **(YES)**
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) **(YES)**
METHODS		
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review **(YES)**
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage **(YES)**
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated **(YES)**
Study records:		

Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review **(YES)**
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) **(YES)**
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators **(YES)**
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications **(YES)**
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale **(YES)**
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis **(YES)**
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised **(YES)**
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2, Kendall's τ) **(YES)**
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) **(YES)**
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned **(YES)**
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) **(YES)**
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE) **(YES)**

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.